TD Cowen raised the firm’s price target on Boston Scientific (BSX) to $100 from $86 and keeps a Buy rating on the shares. The firm believes they will beat the Street’s 3Q estimates and once again raise its guidance. The company is experiencing impressive momentum with several key drivers, including Farapulse, which continues to take share from both RF and cryo.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $98 from $88 at Canaccord
- Is BSX a Buy, Before Earnings?
- Boston Scientific launches next-gen cardiac mapping for FARAPULSE
- Netflix reports Q3 beat, CVS CEO Lynch steps down: Morning Buzz
- Boston Scientific downgraded, Datadog upgraded: Wall Street’s top analyst calls